Proteus Biomedical raised $25 million in a Series E funding round, from investors including Medtronic, Novartis and ON Semiconductor, for developing, manufacturing and commercializing intelligent medicine products.
Such products include Proteus' Raisin personal monitor, a wireless device used to remotely monitor heart rate, physical activity, body position and events logged by the patient. The company received 510(k) clearance for the device, which uses Bluetooth technology and is worn on the skin with an adhesive layer.
"This product clearance represents the first component of our integrated approach to patient-centric, anywhere, anytime mobile health products," said Andrew Thompson, Proteus president and CEO.
- read Proteus' release for more
- check out the Silicon Valley/San Jose Business Journal report
ALSO: Rheonix completed a $12.6 million Series A round, led by the Cayuga Venture Fund and Bill and Eric Allyn. The money will be used to continue developing the Chemistry And Reagent Device diagnostic platform. Release